Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma

Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation. The purpose of this clinical trial was to assess the efficacy of combining belinostat...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Karen, Ramesh, Karthik, Huang, Vicki, Gurbani, Saumya S., Cordova, James Scott, Schreibmann, Eduard, Weinberg, Brent D., Sengupta, Soma, Voloschin, Alfredo D., Holdhoff, Matthias, Barker, Peter B., Kleinberg, Lawrence R., Olson, Jeffrey J., Shu, Hui-Kuo G., Shim, Hyunsuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938806/
https://www.ncbi.nlm.nih.gov/pubmed/35314634
http://dx.doi.org/10.3390/tomography8020057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938806/
https://www.ncbi.nlm.nih.gov/pubmed/35314634
http://dx.doi.org/10.3390/tomography8020057

Ejemplares similares